Increasing evidence suggests that deubiquitinase USP7 participates in tumor progression by various mechanisms and serves as a potential therapeutic target.
ubiqutinated proteins by hydrolyzing the ubiquitin chain on the substrates. [8] [9] [10] Aberrant DUB activity is involved in numerous diseases, especially in tumor progression. 11, 12 Deubiquitinase USP7, also known as HAUSP was first reported by Everett et al 13 as a novel member of the ubiquitin-specific protease family to interact with Herpes simplex virus type one immediate-early protein Vmw110 and to participate in the early stages of viral infection. Recent reports showed that USP7/HAUSP regulated many substrates and was closed to tumor progression, [14] [15] [16] [17] [18] [19] [20] [21] DNA damage, 22, 23 epigenetic regulation, [24] [25] [26] and immune response. 27 Overexpression of USP7/HAUSP was associated with several tumors' poor prognosis, [14] [15] [16] [17] tumor differentiation, 18 or migration and invasion. 14, 15, 19 On the other hand, USP7/HAUSP might act as tumor suppressor in NSCLCs through p53-dependent pathways. 20 Moreover, interestingly, either very low or high levels of USP7 were both associated with poor outcome of breast cancer. 21 These reports showed that USP7 play an essential role in tumor progression in a tumor-specific manner.
Several inhibitors targeting USP7/HAUSP were screened and exhibited anti-tumor effect. 16, 25, [28] [29] [30] [31] [32] Chauhan et al 25 discovered that P5091 exhibited specific and selective deubiquitylating activity against USP7 and did not inhibit other DUBs. P5091 significantly inhibited HCT116 (wt) cells growth; conversely, a slight effect on HCT116 USP7 −/− cells, which suggested that P5091 specifically targeted USP7. 25 Meanwhile, P5091 induced apoptosis in multiple myeloma cells resistant to conventional and bortezomib therapies. 25 Additionally, P5091 could effectively suppress ovarian 33 and colorectal cancer 34 cells growth, cause cell cycle blockage, and induce necrosis and apoptosis.
However, the expression and role of USP7 in esophageal squamous cell carcinoma remains to be elucidated and anti-cancer effect of USP7
inhibitor on esophageal cancer cell growth still needs to be explored.
Here we found that USP7 was overexpressed in esophageal squamous cell carcinoma tissues compared with adjacent tissues. Pharmaceutical or genetic inactivation of USP7 led to the suppression of ESCC cells in vitro or in murine models and induced NOXA-mediated apoptosis.
Mechanistically, inhibition of USP7 triggered endoplasmic reticulum stress; led to the accumulation of ATF4, and thus transcriptionally upregulated the expression of NOXA. These results imply that USP7
could serve as an attractive anti-ESCC target. representative of at least three independent experiments. C, P5091 caused mitochondrial membrane depolarization. Kyse450, Kyse510, and Kyse30 cells were treated with P5091 as indicated. Mitochondrial membrane depolarization was detected as described in Materials and Methods. Cells that had lost mitochondrial membrane potential (MMP) were collected and analyzed by FACS. D, Treatment with P5091 increased the cleavage of CASP9, CASP3, and PARP. ESCC cells Kyse450, Kyse510, and Kyse30 were treated with P5091 for 72 h and cell lysates were assessed by Western blotting with specific antibodies against cleaved CASP9, CASP3, or PARP. GAPDH was used as a control. * means P < 0.05, ** means P < 0.01 sample, the mRNA abundance was normalized to the amount of GAPDH. Primers are as follows: NOXA: forward, 5′-GGA-GATGCCTGGGAAGA-3′, reverse, 5′-TTCTGCCGGAAGTTCAGT-3′; GAPDH: forward, 5′-AAAGGGTCATCATCTCTG-3′, reverse, 5′-GCTGTTGTCATACTTCTC-3′.
| Evaluation of mitochondrial membrane depolarization

| Subcutaneous transplantation tumor model of human esophageal cancer and treatment
Balb/c nude female mice were subcutaneously injected with 5 × 10 6 Kyse450 cells as previously described. 35 
| Statistical analysis
In Figure 1B , Mann-Whitney Test was used for data that are not of normal distribution by SPSS software. In other Figures, the statistical significance of differences between groups was assessed using GraphPad Prism 5 software. The t-test was used for the comparison of parameters between groups. *means P < 0.05, **means P < 0.01.
| RESULTS
| USP7 is overexpressed in human esophageal squamous cell carcinoma tissues
To investigate the clinical significance of USP7 in esophageal cancer, the expression of USP7 was firstly examined by IHC staining of the human ESCC tissue array as described in Materials and Methods. Samples were classified into four groups with increasing staining intensity from the weakest (−) to the strongest (+++) ( Figure 1A) . Results of the IHC showed that USP7 was expressed higher in ESCC tissues compared with their corresponding adjacent tissues (P < 0.01) ( Figure 1B) , which was in accordance with the results of Western blotting analysis using fresh primary esophageal cancer tissues and adjacent esophageal tissues as described in Material and Methods ( Figures 1C and 1D) . Furthermore, the higher expression of USP7 protein was positively correlated with lymph node metastasis (P = 0.002, Table 1 ).
| P5091, an inhibitor of USP7, suppresses cell growth of ESCC
To investigate whether USP7 could serve as an anti-ESCC target, the anticancer efficacy of P5091, an inhibitor of USP7 was examined on (Figure 2A ), which was confirmed by cell viability assay ( Figure 2B ) and colony formation assay ( Figure 2C ).
| P5091 triggers apoptosis of ESCC cells
Morphologically, we found that Kyse30, Kyse450, and Kyse510 cells treated with P5091 shrunk and floated in a concentration-dependent manner (Figure 2A ), which implied that P5091 treatment induced cell death. Next, Fluorescence-Activated Cell Sorting (FACS) results showed that P5091 treatment significantly triggered apoptosis according to
AnnexinV-FITC/PI assay ( Figure 3A ) and the increased activity of caspase-3 ( Figure 3B ). Furthermore, P5091 induced the loss of mitochondrial membrane potential (ΔΨm), a classical marker of the activation of intrinsic apoptosis ( Figure 3C ), suggesting that P5091 triggered mitochondrial apoptosis. Similarly, P5091 significantly induced the cleavage of PARP (poly ADP-ribose polymerase), CASP3, and CASP9 ( Figure 3D ).
| NOXA plays a critical role in P5091-induced apoptosis
Next we further investigated the mechanism of P5091-induced apoptosis. The expression of classical pro-apoptotic proteins (NOXA, Bak, Bax, and Bim) and anti-apoptotic proteins (BCL-2, BCL-XL, Livin, Survin, Mcl-1, c-IAP1, c-IAP2, and XIAP) were examined in Kyse450, Kyse30, and Kyse510 cells after P5091 treatment ( Figure 4A ). Among these proteins, the pro-apoptotic protein NOXA was significantly accumulated in all these three ESCC cell lines ( Figure 4A ). Furthermore, down-regulating the expression of NOXA via siRNA effectively suppressed P5091-induced apoptosis, led to the decrease of Annexin V-positive cells ( Figure 4B ) and the reduction of cleaved PAPR ( Figure 4C ). These findings highlighted a pivotal role of NOXA in P5091-induced apoptosis.
3.5 | P5091 triggers endoplasmic reticulum stress and transactivate NOXA by activating transcription factor 4
Previous reports showed that NOXA could be transactivated by several transcription factors (TFs). 47 We screened the expression of related TFs including p53, ATF4, cMyc, HIF1α, and FOXO3. Results showed that P5091 treatment increased the protein level of Activating transcription factor 4 (ATF4) while other TFs changed slightly ( Figure 5A ). Next we determined whether P5091-induced NOXA expression was mediated by ATF4 in ESCC cells. Results showed that knockdown of ATF4 effectively attenuated the P5091-induced apoptosis ( Figure 5B ) and reduced the cleavage of PARP ( Figure 5C ). Moreover, ATF4 knockdown significantly inhibited the FIGURE 6 Knockdown of USP7 by siRNA inhibits ESCC cell growth and induces apoptosis. A, Silencing USP7 inhibited cell growth. Kyse450 and Kyse510 cells were transfected with siRNA targeting USP7 for 96 h and cell viability was assessed by CCK-8 assay. B, Silencing USP7 triggered apoptosis. Kyse450 and Kyse510 cells were transfected with siRNA targeting USP7 for 96 h and apoptosis was assessed by Annexin V-TITC/PI apoptosis assay. C, Silencing USP7 accumulated ubiquitinated proteins and increased the expression of ATF4, NOXA and cleaved PARP. Kyse450 and Kyse510 cells were transfected with siRNA targeting USP7 for 96 h and cell lysates were assessed by Western blotting with specific antibodies against Ub, ATF4, NOXA, and cleaved PARP. GAPDH was used as a loading control induction of NOXA at both protein ( Figure 5C ) and mRNA levels ( Figure 5D ) in both Kyse450 and Kyse510 cells. Further results showed that P5091 treatment accumulated the poly-ubiquitinated proteins ( Figure 5E ), which activated the endoplasmic reticulum stress, as evidenced by increasing expression of ER stress related proteins, including BiP (also known as GRP78), p-EIF2α, CHOP, and ATF4
( Figures 5A and 5E ).
3.6 | Genetic inactivation of USP7 recapitulates P5091-induced cell growth inhibition effect on ESCC cells
To further detect the effect of USP7 inhibition on ESCC cell growth, we inactivated USP7 using specific siRNAs and determined whether genetic inactivation of USP7 could recapitulate the cell growth inhibition effect on ESCC cells. Consistent with P5091 treatment, knockdown of USP7 inhibited cell viability in both Kyse450 and Kyse510 cells ( Figure 6A ). Moreover, silencing USP7 also induced apoptosis ( Figure 6B ) and increased the expression of cleaved PARP ). E, Proteins extracted from tumor tissues were analyzed by Western blotting using ATF4, cleaved PARP, and NOXA antibodies. GAPDH was used as a loading control address the potential mechanisms for the anti-tumor activity of P5091, we determined whether the ATF4/NOXA axis was activated in vivo. As shown in Figure 7E , the expression of ATF4, NOXA, and cleaved PARP were significantly induced by P5091 treatment ( Figure 7E ). These observations indicated that P5091 inhibited esophageal tumor growth both in vitro and in vivo via the ATF4/NOXA apoptosis pathway. A serious of inhibitors targeting USP7 was evaluated in vitro and in vivo studies. 25, [30] [31] [32] 53, 54 In which, P5091 was identified as a specific inhibitor of USP7 25 and showed a promising anti-cancer effect in several tumors. 25, 34, 51, 55, 56 Here, we found that inactivation of USP7 using P5091 effectively inhibited esophageal cancer cell growth in vitro and in vivo. At the same time, we found that different cell lines exhibited slightly different sensitivity to P5091, which was in accordance with previous reports. 25, 51 Our results found that the expression of USP7 was cell-dependent (unpublished data). Additionally, reports showed that USP7 could be self-activated 57 or regulated by several other factors, 58 including post-translational modification (PTM) 58, 59 or miRNA 60 under different conditions. Future in-depth study will be performed to elucidate the difference of sensitivity between different cell lines.
P5091 exert its anti-tumor effect through a different mechanism.
In multiple myeloma cells, P5091 treatment inhibited cell proliferation and induced apoptosis in a p53-independent manner. 25 Additionally, P5091 could inhibit colon cancer cells growth by inhibiting Wnt signaling. 34 In neuroendocrine tumors of the lung, P5091 enhanced the drug sensitivity by downregulating the expression of CCDC6 to regulate the DNA repair. 56 Here we found that P5091 treatment induced ATF4/NOXA-mediated apoptosis in ESCC cell lines. Recently, NOXA has been identified as a pivotal factor responding to chemotherapy. 47, [61] [62] [63] The role and mechanism of NOXA-mediated apoptosis are diverse in different cells or using specific drug treatment. 64 NOXA could be transactivated by several transcription factors. 47, 64 Here we found that the change of p53, FOXO3, cMyc, and HIF-1α was slight after P5091 treatment, while the expression of ATF4 increased obviously. Previous reports suggested that BCL-2 family proteins play an important role in Unfolded Protein Response (UPR) 65 and the activation of UPR, including endoplasmic reticulum stress was an important mechanism response to DUB inhibition. 51, 66 Meanwhile, eIF2α-ATF4 plays a key role in NOXA activation and NOXA-mediated apoptosis. 35 In accordance with these studies, our results found that P5091 treatment led to the accumulation of poly-ubiquitinated proteins, which triggered endoplasmic reticulum stress and activated ATF4. Silencing ATF4 effectively rescued the P5091-induced expression of NOXA and P5091-related apoptosis, implied that ATF4-NOXA partially responsible for the cell growth inhibition of esophageal cancer in vitro and in vivo by P5091 treatment.
Collectively, this study reported that targeting USP7 triggered NOXA-mediated apoptosis and inhibited ESCC cell growth in vitro and in vivo. These findings provide strong impetus for the clinical investigation of deubiquitinase inhibitors for the treatment of ESCC.
